JP2005504517A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005504517A5 JP2005504517A5 JP2002592353A JP2002592353A JP2005504517A5 JP 2005504517 A5 JP2005504517 A5 JP 2005504517A5 JP 2002592353 A JP2002592353 A JP 2002592353A JP 2002592353 A JP2002592353 A JP 2002592353A JP 2005504517 A5 JP2005504517 A5 JP 2005504517A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- acid sequence
- variant
- variable region
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical group 0.000 claims 11
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 8
- 230000004927 fusion Effects 0.000 claims 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 239000000126 substance Substances 0.000 claims 6
- 230000036252 glycation Effects 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 229910052702 rhenium Inorganic materials 0.000 claims 2
- WUAPFZMCVAUBPE-UHFFFAOYSA-N rhenium atom Chemical compound [Re] WUAPFZMCVAUBPE-UHFFFAOYSA-N 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 108020004511 Recombinant DNA Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000005250 beta ray Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229910052727 yttrium Inorganic materials 0.000 claims 1
- VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01112237 | 2001-05-18 | ||
| US32514701P | 2001-09-26 | 2001-09-26 | |
| PCT/EP2002/005467 WO2002094879A1 (en) | 2001-05-18 | 2002-05-17 | Antibodies specific for cd44v6 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005504517A JP2005504517A (ja) | 2005-02-17 |
| JP2005504517A5 true JP2005504517A5 (enExample) | 2006-01-05 |
Family
ID=33442672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002592353A Pending JP2005504517A (ja) | 2001-05-18 | 2002-05-17 | ＣＤ４４ｖ６特異的抗体 |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1397387A1 (enExample) |
| JP (1) | JP2005504517A (enExample) |
| CN (1) | CN1541226A (enExample) |
| AR (1) | AR036154A1 (enExample) |
| BR (1) | BR0210905A (enExample) |
| CA (1) | CA2443437A1 (enExample) |
| CZ (1) | CZ20033476A3 (enExample) |
| EA (1) | EA200301169A1 (enExample) |
| EC (1) | ECSP034838A (enExample) |
| EE (1) | EE200300569A (enExample) |
| HU (1) | HUP0400030A3 (enExample) |
| MX (1) | MXPA03010523A (enExample) |
| PE (1) | PE20021098A1 (enExample) |
| PL (1) | PL365735A1 (enExample) |
| SK (1) | SK15592003A3 (enExample) |
| WO (1) | WO2002094879A1 (enExample) |
| YU (1) | YU91403A (enExample) |
| ZA (1) | ZA200307365B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050100542A1 (en) | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US8071072B2 (en) | 1999-10-08 | 2011-12-06 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7947496B2 (en) | 1999-10-08 | 2011-05-24 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US8048416B2 (en) | 1999-10-08 | 2011-11-01 | Hoffmann-La Roche Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7189397B2 (en) | 1999-10-08 | 2007-03-13 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US7084257B2 (en) | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| AU2005214331B2 (en) | 2004-02-12 | 2011-09-15 | Eisai, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| ES2429340T3 (es) | 2005-03-10 | 2013-11-14 | Morphotek, Inc. | Anticuerpos anti-mesotelina |
| AU2006241099B2 (en) | 2005-04-22 | 2012-04-19 | Eisai, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| DK2167038T3 (en) * | 2007-06-13 | 2018-08-06 | Zymogenetics Inc | USING TACI-IG FUSION PROTEIN AS ATACICEPT TO PREPARE A MEDICINE FOR TREATING LUPUS ERYTHEMATOSUS |
| EP2009028A1 (en) * | 2007-06-27 | 2008-12-31 | Monoclonal Antibodies Therapeutics | Combination of a conventional anti-cancer treatment with anti-CD44 antibody administration for treating solid tumors |
| AU2011212485B2 (en) | 2010-02-04 | 2014-04-17 | University Of Miami | A monoclonal antibody to CD44 for use in the treatment of head and neck squamous cell carcinoma |
| CN102337298B (zh) * | 2011-08-19 | 2013-11-06 | 黄开红 | 一种输送siRNA的免疫纳米载体及其制备方法和应用 |
| US20140335084A1 (en) | 2011-12-06 | 2014-11-13 | Hoffmann-La Roche Inc. | Antibody formulation |
| WO2017215637A1 (zh) * | 2016-06-15 | 2017-12-21 | 李翀 | 一种人子宫内膜癌的标志物、抗体及其应用 |
| CN107556388A (zh) * | 2016-06-30 | 2018-01-09 | 中国科学院深圳先进技术研究院 | 抗CD44v6和CD3特异性双靶向抗体、含该双靶向抗体表达盒的微环DNA及应用 |
| JP2023516080A (ja) * | 2020-03-06 | 2023-04-17 | ジーオー セラピューティクス，インコーポレイテッド | 抗グリコｃｄ４４抗体およびその使用 |
| US20250326855A1 (en) * | 2021-03-05 | 2025-10-23 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL162181A (en) * | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0438310A1 (en) * | 1990-01-19 | 1991-07-24 | Merck & Co. Inc. | Method for producing recombinant immunoglobuline |
| GB9020282D0 (en) * | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
| WO1994012631A1 (en) * | 1992-11-20 | 1994-06-09 | Isis Innovation Limited | Peptide corresponding to cd44 exon 6, antibodies specific for said peptide and use of these antibodies for diagnosis of tumors |
| UA58482C2 (uk) * | 1994-06-08 | 2003-08-15 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Моноклональне антитіло vff-18 проти сd44v6 і його фрагменти |
| UY24389A1 (es) * | 1995-12-06 | 2001-10-25 | Karlsruhe Forschzent | Composición farmacéutica para el tratamiento de carcinoma de epitelio plano |
-
2002
- 2002-05-17 BR BR0210905-0A patent/BR0210905A/pt not_active IP Right Cessation
- 2002-05-17 AR ARP020101830A patent/AR036154A1/es unknown
- 2002-05-17 JP JP2002592353A patent/JP2005504517A/ja active Pending
- 2002-05-17 YU YU91403A patent/YU91403A/sh unknown
- 2002-05-17 CA CA002443437A patent/CA2443437A1/en not_active Abandoned
- 2002-05-17 PL PL02365735A patent/PL365735A1/xx not_active Application Discontinuation
- 2002-05-17 MX MXPA03010523A patent/MXPA03010523A/es unknown
- 2002-05-17 EA EA200301169A patent/EA200301169A1/ru unknown
- 2002-05-17 SK SK1559-2003A patent/SK15592003A3/sk not_active Application Discontinuation
- 2002-05-17 EE EEP200300569A patent/EE200300569A/xx unknown
- 2002-05-17 PE PE2002000422A patent/PE20021098A1/es not_active Application Discontinuation
- 2002-05-17 HU HU0400030A patent/HUP0400030A3/hu unknown
- 2002-05-17 CN CNA028101561A patent/CN1541226A/zh active Pending
- 2002-05-17 EP EP02735364A patent/EP1397387A1/en not_active Ceased
- 2002-05-17 CZ CZ20033476A patent/CZ20033476A3/cs unknown
- 2002-05-17 WO PCT/EP2002/005467 patent/WO2002094879A1/en not_active Ceased
-
2003
- 2003-09-22 ZA ZA200307365A patent/ZA200307365B/xx unknown
- 2003-11-10 EC EC2003004838A patent/ECSP034838A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005504517A5 (enExample) | ||
| CN1956998B (zh) | 用于纯化白蛋白结合物的方法 | |
| KR100484084B1 (ko) | 키메라성 폴리펩타이드, 이의 제조 방법 및 용도 | |
| CN111763247B (zh) | 白蛋白结合多肽 | |
| JP2006516189A5 (enExample) | ||
| CO5570710A2 (es) | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor de glucagon y sus metodos de uso farmacologico | |
| MXPA04008077A (es) | Anticuerpos ant-a° y su uso. | |
| WO2003000842A3 (en) | Novel proteins and nucleic acids encoding same | |
| JP2007289200A5 (enExample) | ||
| Gallizia et al. | Production of a soluble and functional recombinant streptavidin inescherichia coli | |
| AR036154A1 (es) | Anticuerpos especificos de cd44v6. | |
| JP2004526421A5 (enExample) | ||
| WO2002081498A3 (en) | Novel proteins and nucleic acids encoding same | |
| Maruyama et al. | A novel domain sequence of connectin localized at the I band of skeletal muscle sarcomeres: homology to neurofilament subunits | |
| Proost et al. | Chemical synthesis, purification and folding of the human monocyte chemotactic proteins MCP-2 and MCP-3 into biologically active chemokines | |
| ES2663242T3 (es) | Productos génicos expresados de forma diferencial en tumores y su utilización | |
| WO2003010327A3 (en) | Novel proteins and nucleic acids encoding same | |
| JP2011504361A5 (enExample) | ||
| CN100427506C (zh) | 从融合多肽制备感兴趣的多肽的方法 | |
| JP2020127419A5 (enExample) | ||
| CN102060913A (zh) | 一种与人血清白蛋白结合的七肽与应用 | |
| JP2025036661A (ja) | 抗体酵素の革新的製造技術 | |
| JP2009542243A5 (enExample) | ||
| WO2002072757A3 (en) | Novel proteins and nucleic acids encoding same | |
| JP2003507029A5 (enExample) |